We welcome Isabel Klein to the group. Isabel is in her 3rd year as a chemistry student at Barnard College in Columbia University in New York City. She is spending a semester abroad in UCD and has chosen to spend her research experience with the group. She will work on a carbohydrate chemistry project while she is with us, and gain in-depth experience with 2D-NMR as part of the project.
We welcome Jorge Combarros to the group. Jorge joins the group on a 2-month secondment from Gadea Grupo Farmacéutico in Valladolid (part of AmriGlobal). His project is part of a larger EU collaboration, 3DNet, led by Dr Breandán Kennedy (UCD School of Biomolecular & Biomedical Science, Fellow of the UCD Conway Institute), that involves researchers in the UCD School of Chemistry & Chemical Biology, the University of Valladolid (Spain), and industrial partners in RenaSci Ltd (UK), KalVista Pharmaceuticals (UK), Gadea Grupo Farmacéutico (Spain). There is an unmet clinical need for more effective treatments to halt or reverse eye diseases that lead to blindness (like age-related macular degeneration, diabetic retinopathy, and corneal inflammation) with increasing prevalence as the EU population ages. The European network focuses on the exchange of knowledge, people, and expertise to enhance the discovery and development of drugs that target these ocular pathologies. It is funded by a FP7- Marie Curie IAPP grant.